James Metz, MD

Verginadis II, Velalopoulou A, Kim MM, Kim K, Paraskevaidis I, Bell B, Oliaei Motlagh SA, Karaj A, Banerjee E, Finesso G, Assenmacher CA, Radaelli E, Lu J,Lin Y, Putt ME, Diffenderfer ES, Guha C, Qin L, Metz JM, Maity A, Cengel KA,Koumenis C, Busch TM FLASH proton reirradiation, with or without hypofractionation, reduces chronic toxicity in the normal murine intestine, skin and bone. , RadioTher. Oncology: 2025

Ni H, Reitman ZJ, Zou W, Akhtar MN, Paul R, Huang M, Zhang D, Zheng H, Zhang R, Ma R, Ngo G, Zhang L, Diffenderfer ES, Motlagh SAO, Kim MM, Minn AJ, Dorsey JF, Foster JB, Metz J, Koumenis C, Kirsch DG, Gong Y, Fan Y. FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy. , Nat. Cancer: 2025

Lee G, Nelson B, Koenig J, Plastaras JP, Metz JM, Yeap BY, Zhang Y, Drapek LC, Baglini C, Ryan DP, Parikh AR, Allen JN, Clark JW, Blaszkowsky LS, Ben-Josef E, Hong TS, Kharofa JR, Wo JY. Long-term Outcomes of Definitive Chemoradiation With Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of 2 Prospective Trials. , Int. J Radiation Oncology-Biology-Physics: 2025

Amit U, Shagun M, Plastaras JP, Metz JM, Karasic TB, Lubas MJ, Ben-Josef E. Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy. , Radiation Oncology: 2024

Hartsell WF, Simone CB 2nd, Godes D, Maggiore J, Mehta MP, Frank SJ, Metz JM, Choi JI. Temporal Evolution and Diagnostic Diversification of Patients Receiving Proton Therapy in the United States: A Ten-Year Trend Analysis (2012 to 2021) From the National Association for Proton Therapy. , Int. J Radiation Oncology-Biology-Physics: 2024

erginadis II, Velalopoulou A, Kim MM, Kim K, Paraskevaidis I, Bell B, Oliaei Motlagh SA, Karaj A, Banerjee E, Finesso G, Assenmacher CA, Radaelli E, Lu J, Lin Y, Putt ME, Diffenderfer ES, Guha C, Qin L, Metz JM, Maity A, Cengel KA, Koumenis C, Busch TM. FLASH proton reirradiation, with or without hypofractionation, mitigates chronic toxicity in the normal murine intestine, skin, and bone. , bioRxiv [Preprint]: 2024

Chowdhury P, Velalopoulou A, Verginadis II, Morcos G, Loo PE, Kim MM, Motlagh SAO, Shoniyozov K, Diffenderfer ES, Ocampo EA, Putt M, Assenmacher CA, Radaelli E, Lu J, Qin L, Liu H, Leli NM, Girdhani S, Denef N, Vander Stappen F, Cengel KA, Busch TM, Metz JM, Dong L, Lin A, Koumenis C. Proton FLASH Radiotherapy Ameliorates Radiation-induced Salivary Gland Dysfunction and Oral Mucositis and Increases Survival in a Mouse Model of Head and Neck Cancer. , Mol Cancer Therapy.: 2024

Bakhtiar M, Butala AA, Berlin EE, Metz JM, Bradley JD, Jones JA, Lukens JN, Paydar I, Taunk NK Factors Associated With and Characteristics of Patients Receiving Proton Therapy at the End of Life. , International Journal Particle Therapy: 2024

Jimenez RB, Pinnix CC, Juang T, Franco I, Sim AJ, Siker M, Vapiwala N, Chino F, Shinohara ET, Metz J, Winkfield KM, Suneja G, Deville C Jr, Gibbs IC. Using Holistic Residency Applicant Review and Selection in Radiation Oncology to Enhance Diversity and Inclusion-An ASTRO SCAROP-ADROP-ARRO Collaboration , Int. J Radiation Oncology-Biology-Physics: 2023

Raldow AC, Siker ML, Bonner JA, Chen Y, Liu FF, Metz JM, Movsas B, Potters L, Schultz CJ, Wilson E, Wang X, Romero T, Steinberg ML, Jagsi R. Assessment of Differences in Academic Rank and Compensation by Gender and Race/Ethnicity Among Academic Radiation Oncologists in the United States. , Advanced Radiation Oncology: 2023